Abstract:Abstract Tumor-initiating cells (TICs) or so-called cancer stem cells (CSCs) are a minor subpopulation of poor differentiated cells that are responsible for tumor initiation, maintenance, and spreading. Hence, eliminating these cells is supposed to be an effective way of the treatment of cancer. By immunizing mice with TIC-enriched hepatocellular carcinoma (HCC) cells (Xu XL, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogensis. 2010; 31:167-74.) and by subsequent hybridoma technique, we have obtained an antibody 1B50-1, which recognizes the antigen of a 150 KD ion channel-composing protein. Despite the percentage of 1B50-1 positive cells varies from <1% to ∼90% in established hepatocellular carcinoma cell lines, the administration of this antibody by i.p. injection at a dose of 40mg/kg could suppress the growth of HCC cell lines’ engraftments in NOD/SCID mice with an inhibition rate that could be as high as 87%, comparing with control groups. Furthermore, 100 of 1B50-1 positive cells, but not the negative compartments, from several HCC cell lines were sufficient to initiate tumor growth in NOD/SCID mice, and displayed self-renewal ability as demonstrated by serial transplantation assay in mice. The 1B50-1 positive cells also expressed higher levels of Nanog, Sox-2, and Oct 4 than the negative ones. Immunohistochemical staining of 29 HCC specimen with 1B50-1 has revealed that only a small population of positive cells were scattered in 16 HCC tissues, and that these cells with similar distribution pattern were only found in 4 out of 12 paracancerous tissues. These data suggest that the antigen for 1B50-1 is a new marker for HCC tumor-initiating cells, and that it is a promising target for HCC molecular therapy. 1B50-1 is worthy of further developing into drug for the treatment of HCC. Funding: This study was supported by the National Basic Research Program of China (973 Program, No 2010CB529402), National Natural Science Foundation of China, and “863” Program (2008AA02Z108). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1666. doi:10.1158/1538-7445.AM2011-1666

Abstract 1666: Targeting Tumor-Initiating Cells for the Treatment of Hepatocellular Carcinoma